RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Puma Biotechnology Stock

Puma Biotechnology P/E 2024

Puma Biotechnology P/E

13.91

Ticker

PBYI

ISIN

US74587V1070

WKN

A1J643

As of Nov 8, 2024, Puma Biotechnology's P/E ratio was 13.91, a 83.51% change from the 7.58 P/E ratio recorded in the previous year.

The Puma Biotechnology P/E history

Puma Biotechnology Aktienanalyse

What does Puma Biotechnology do?

Puma Biotechnology Inc. is a biopharmaceutical company based in Los Angeles. It was founded in 2010 and initially focused on the development of innovative cancer treatments. Since then, the company has significantly expanded and now offers a wide range of products and services all centered around cancer treatment. The company's business model revolves around developing drugs that address the need for novel and effective therapies to treat cancer. Puma Biotechnology Inc. is a leading player in this field and has already brought several successful products to market. One of the company's most well-known cancer treatments is Neratinib (also known as Nerlynx), which is used to treat breast cancer. Nerlynx received FDA approval in July 2017. Puma Biotechnology Inc. was founded in 2010 by Alan H. Auerbach, who had previously founded the biopharmaceutical company Cougar Biotechnology and successfully sold it to Johnson & Johnson. The history of Puma Biotechnology Inc. is marked by continuous growth. After its founding, the company acquired exclusive rights to develop neratinib for the treatment of breast cancer. The company has since conducted numerous studies and collected clinical data to prove the efficacy and safety of Nerlynx. After years of research, the medication finally received FDA approval in 2017. Puma Biotechnology Inc. has expanded its offerings since its founding and now offers a wide range of products and services centered around cancer treatment. One of the company's main areas of focus is research and development of cancer treatments. Puma Biotechnology Inc. continuously works on developing new drugs and therapies for a variety of cancer types, including breast cancer, lung cancer, and leukemia. The company is also involved in the production and marketing of pharmaceuticals. Neratinib is the company's most well-known product, but Puma Biotechnology Inc. has also brought other cancer treatments to the market. Additionally, Puma Biotechnology Inc. offers a wide range of services in the field of cancer treatment. The company is involved in the development of diagnostics and preventative measures and also offers training and consultations for doctors and patients. Nerlynx is Puma Biotechnology Inc.'s most well-known product and is now distributed worldwide. The medication is an oral therapeutic used for the adjuvant treatment of early-stage HER2-positive breast cancer in adults following adequate standard adjuvant therapy. It is taken by women who have already undergone chemotherapy, surgery, and radiation therapy. Neratinib works to prevent cancer recurrences by targeting the HER2 receptor, which normally promotes cancer cell growth. The medication blocks these receptors and can therefore inhibit tumor growth. In addition, Puma Biotechnology Inc. has also brought other products to the market, including Ribociclib, which is used in combination with other medications to treat ER-positive, HER2-negative breast cancer. In conclusion, Puma Biotechnology Inc. is a unique and emerging company with a focus on cancer treatments. Since its founding in 2010, the company has become a leading player in cancer combat. Puma Biotechnology Inc. is involved in the development of innovative therapeutic approaches, has achieved numerous medical successes, and brought many promising medications to the market. With Nerlynx, the company has introduced an effective medication for the treatment of breast cancer, and its potential is far from being realized. The company will undoubtedly play an important role in the treatment of cancer in the future. Puma Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Puma Biotechnology's P/E Ratio

The Price to Earnings (P/E) Ratio of Puma Biotechnology is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Puma Biotechnology's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Puma Biotechnology is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Puma Biotechnology’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Puma Biotechnology stock

What is the price-to-earnings ratio of Puma Biotechnology?

The price-earnings ratio of Puma Biotechnology is currently 13.91.

How has the price-earnings ratio of Puma Biotechnology changed compared to last year?

The price-to-earnings ratio of Puma Biotechnology has increased by 83.51% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Puma Biotechnology high compared to other companies?

Yes, the price-to-earnings ratio of Puma Biotechnology is high compared to other companies.

How does an increase in the price-earnings ratio of Puma Biotechnology affect the company?

An increase in the price-earnings ratio of Puma Biotechnology would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Puma Biotechnology affect the company?

A decrease in the price-earnings ratio of Puma Biotechnology would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Puma Biotechnology?

Some factors that influence the price-earnings ratio of Puma Biotechnology are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Puma Biotechnology pay?

Over the past 12 months, Puma Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Puma Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of Puma Biotechnology?

The current dividend yield of Puma Biotechnology is .

When does Puma Biotechnology pay dividends?

Puma Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Puma Biotechnology?

Puma Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Puma Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Puma Biotechnology located?

Puma Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Puma Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Puma Biotechnology from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Puma Biotechnology pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Puma Biotechnology in the year 2023?

In the year 2023, Puma Biotechnology distributed 0 USD as dividends.

In which currency does Puma Biotechnology pay out the dividend?

The dividends of Puma Biotechnology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Puma Biotechnology

Our stock analysis for Puma Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Puma Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.